Observational study to describe the impact of treatment combinations with Daratumumab versus other alternative regimens in patients with relapsed / refractory multiple myeloma. Spain real world evidence (RWE) data. GeminiS study

Autor:	Jose Luis Sanchez-Majano Suarez-Llanos, Rafael Ríos Tamayo, Maria-Victoria Mateos, Antonio Garcia Guiñon, Miriam Gonzalez Pardo, Carolina Leiva Farre, Mario Arnao Herraiz, Sebastian Garzon Lopez, Juan Alfons Soler, abel domingo garcía, Javier de la Rubia, Ana López de la Guía
Rok vydání:	2019
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry Daratumumab Hematology medicine.disease Real world evidence Internal medicine Relapsed refractory medicine In patient Observational study business Multiple myeloma
Zdroj:	Clinical Lymphoma Myeloma and Leukemia. 19:e147
ISSN:	2152-2650
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::f33561b2a7a7b318c7806296888903c2 https://doi.org/10.1016/j.clml.2019.09.245 Zobrazit plný text záznamu Full Text from ScienceDirect